Alumis Inc. - Common Stock (ALMS)

Synergy CHC Corp. (NASDAQ: SNYR) is gaining renewed investor attention as its FOCUSfactor® functional beverage platform scales rapidly through the Company’s already-established retail ecosystem—built on the strength of its 25-year FOCUSfactor® brain health supplement legacy . By leveraging long-standing national distribution relationships, Synergy is accelerating beverage adoption without the execution risk typically associated with launching a new consumer brand.This beverage expansion underpins Roth Capital Partners’ Buy rating and 12-month $7 price target on SNYR. Roth projects revenues could grow from approximately $35.4 million in 2025 to nearly $55 million in 2026, driven largely by beverage penetration layered onto Synergy’s existing retail and wholesale channels.

– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis –

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction.

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN’s development programs or intellectual property.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. is fair to Alumis shareholders. Upon closing of the proposed transaction, Alumis shareholders will own approximately 55% of the combined company.

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September:

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission –